Cellular health screening market seen reaching $6.31 billion by 2030

The cellular health screening market is projected to grow from $4.16 billion in 2026 to $6.31 billion by 2030, driven by rising chronic disease rates, personalized medicine and earlier diagnosis tools. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Cellular health screening is expanding as health systems push harder on early detection, preventive care and precision medicine. - The market outlook points to rising demand for tests that can identify cellular and inflammatory issues before they become more serious conditions. - Chronic disease prevalence is a major demand driver, creating a larger need for ongoing screening and monitoring.

What happened: - The Business Research Company published its Cellular Health Screening Global Market Report 2026, projecting the market will rise from $4.16 billion in 2026 to $6.31 billion by 2030. - The report forecasts an 11.0% CAGR through 2030. - The market was valued at $3.76 billion in 2025. - The report says the market has already been growing at 10.8% CAGR in the historical period, reaching $4.16 billion in 2026. - The report describes cellular health screening as medical tests that assess inflammatory and other cellular conditions using samples from cells, tissues or organs. - The tests can use blood, urine or imaging techniques. - The report says the main purpose is to provide fast, detailed insight at the cellular level to support quicker diagnosis and targeted intervention. - The release includes a free sample of the market report. - The release also points to the full market report.

The details: - Growth over the historical period is linked to rising chronic inflammatory disease prevalence, stronger preventive healthcare focus, expansion of diagnostic laboratories, more blood-based diagnostic testing and better validation of clinical biomarkers. - Forward growth is tied to greater demand for personalized medicine, wider use of early disease detection technologies, expansion of remote and home-based diagnostics, AI-powered diagnostic analytics and more investment in precision health screening. - Key trends include multi-panel cellular diagnostics, biomarker-based screening tests, home sample collection kits, faster cellular inflammation testing and more preventive health monitoring. - The report says cellular health screening can help identify people at risk from genetic factors, lifestyle habits, environmental influences or underlying health problems. - The CDC reported in April 2025 that nearly 194 million U.S. adults, or 76.4% of the adult population, had at least one chronic condition in 2023. - The CDC data breaks down chronic condition prevalence at 59.5% for younger adults, 78.4% for middle-aged adults and 93.0% for older adults. - North America held the largest share of the market in 2025. - Asia-Pacific is forecast to be the fastest-growing region over the coming years. - The report covers Asia-Pacific, South East Asia, Western and Eastern Europe, North and South America, and the Middle East and Africa. - The 2026 report update adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables.

Between the lines: - The market’s growth is being pulled by both clinical need and technology adoption, which suggests screening is moving from a niche diagnostic tool toward a broader preventive-health workflow. - The combination of home collection, remote diagnostics and AI analytics points to a shift toward more distributed and more automated testing models. - North America’s lead and Asia-Pacific’s expected growth suggest the market is maturing in established healthcare systems while scaling fastest where diagnostic adoption is still expanding.

What's next: - The report expects continued growth through 2030 as providers and consumers adopt more preventive and personalized screening. - The company says it is offering further market materials and expert contact points for buyers seeking more detail. - The report’s regional and technology forecasts will likely shape investment decisions across diagnostics, digital health and precision medicine.